XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Schedule of Restrictions on Cash and Cash Equivalents The following table provides a reconciliation of the total cash, cash equivalents and restricted cash reported on the Condensed Consolidated Balance Sheets to the corresponding amounts reported on the Condensed Consolidated Statements of Cash Flows.
March 31,
2024		March 31,
2023
Cash and cash equivalents$263 $321 
Restricted cash45 82 
Cash, cash equivalents and restricted cash$308 $403 
Schedule of Cash and Cash Equivalents The following table provides a reconciliation of the total cash, cash equivalents and restricted cash reported on the Condensed Consolidated Balance Sheets to the corresponding amounts reported on the Condensed Consolidated Statements of Cash Flows.
March 31,
2024		March 31,
2023
Cash and cash equivalents$263 $321 
Restricted cash45 82 
Cash, cash equivalents and restricted cash$308 $403 
Schedule of Shares Used in Computing Basic and Diluted Earnings Per Share Shares used in computing basic and diluted earnings per share are as follows: 
Three Months Ended
March 31,		Six Months Ended
March 31,
 2024202320242023
Denominator (thousands of shares):
Weighted-average common shares outstanding — basic209,826 209,857 209,789 209,902 
Incremental shares issuable for stock options, common stock awards and Equity Units (a)5,419 6,263 5,604 — 
Weighted-average common shares outstanding — diluted215,245 216,120 215,393 209,902 
(a)For the three months ended March 31, 2024 and 2023, 8,659 and 5,980 shares, respectively, associated with outstanding stock option awards were excluded from the computation of diluted earnings per share above because their effect was antidilutive. For the six months ended March 31, 2024, 8,468 shares associated with outstanding stock option awards were excluded from the computation of diluted earnings per share above because their effect was antidilutive. For the six months ended March 31, 2023, 6,348 of such shares have been excluded as such incremental shares would be antidilutive due to the net loss for the period.